- Home
- NTIP vs RNXT Comparison
NTIP vs RNXT Comparison
Compare NTIP & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- RNXT
- Stock Information
- Founded
- NTIP 1990
- RNXT 2012
- Country
- NTIP United States
- RNXT United States
- Employees
- NTIP N/A
- RNXT N/A
- Industry
- NTIP Multi-Sector Companies
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- RNXT Health Care
- Exchange
- NTIP Nasdaq
- RNXT Nasdaq
- Market Cap
- NTIP 28.6M
- RNXT 44.6M
- IPO Year
- NTIP 1998
- RNXT 2021
- Fundamental
- Price
- NTIP $1.23
- RNXT $1.30
- Analyst Decision
- NTIP
- RNXT Strong Buy
- Analyst Count
- NTIP 0
- RNXT 2
- Target Price
- NTIP N/A
- RNXT $7.25
- AVG Volume (30 Days)
- NTIP 13.9K
- RNXT 141.1K
- Earning Date
- NTIP 08-11-2025
- RNXT 08-12-2025
- Dividend Yield
- NTIP 8.00%
- RNXT N/A
- EPS Growth
- NTIP N/A
- RNXT N/A
- EPS
- NTIP N/A
- RNXT N/A
- Revenue
- NTIP $250,000.00
- RNXT $240,000.00
- Revenue This Year
- NTIP N/A
- RNXT $3,186.05
- Revenue Next Year
- NTIP N/A
- RNXT $291.93
- P/E Ratio
- NTIP N/A
- RNXT N/A
- Revenue Growth
- NTIP N/A
- RNXT N/A
- 52 Week Low
- NTIP $1.16
- RNXT $0.75
- 52 Week High
- NTIP $1.78
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- NTIP 49.11
- RNXT 48.98
- Support Level
- NTIP $1.20
- RNXT $1.27
- Resistance Level
- NTIP $1.30
- RNXT $1.38
- Average True Range (ATR)
- NTIP 0.05
- RNXT 0.06
- MACD
- NTIP -0.00
- RNXT -0.01
- Stochastic Oscillator
- NTIP 49.29
- RNXT 23.23
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.